Last updated on January 2019

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer


Brief description of study

This trial studies SGN-LIV1A in combination with pembrolizumab to find out what their side effects are and if they work for patients with triple-negative breast cancer that has spread to other parts of the body. Patients will be given both experimental drugs every 3 weeks.

Detailed Study Description

The primary goal of this study is to evaluate the combination of SGN-LIV1A, which targets LIV-1- expressing tumor cells, with the checkpoint inhibitor pembrolizumab for patients with unresectable locally-advanced or metastatic triple-negative breast cancer. These two drugs act through distinct and possibly complementary modes of action.

This is a single-arm, open-label, multicenter trial. Patients given SGN-LIV1A and pembrolizumab in Part A will be monitored for frequency of dose-limiting toxicities to determine if SGN-LIV1A dosing should be de-escalated before opening the expansion in Part B. In addition to safety measures, objective response rate, progression-free survival, overall survival, and other efficacy outcomes will be assessed.

Clinical Study Identifier: NCT03310957

Contact Investigators or Research Sites near you

Start Over

Ursa Brown-Glaberman, MD

University of New Mexico Cancer Center
Albuquerque, NM United States
  Connect »

Ritesh Parajuli

Chao Family Comprehensive Cancer Center University of California Irvine
Orange, CA United States
  Connect »

Michael Guarino

Helen F. Graham Cancer Center / Christiana Care Health Systems
Newark, DE United States
  Connect »

Kimberly Kruczek

Ingalls Cancer Care / Ingalls Memorial Hospital
Harvey, IL United States
  Connect »

Katherine H. R. Tkaczuk

University of Maryland
Baltimore, MD United States
  Connect »

Michaela Tsai

Virginia Piper Cancer Institute
Minneapolis, MN United States
  Connect »

Adam Brufsky

Hillman Cancer Center / University of Pittsburgh Medical Center
Pittsburgh, PA United States
  Connect »

Carlos Alemany

Cancer Institute of Florida
Orlando, FL United States
  Connect »

Jane Meisel

Winship Cancer Institute / Emory University School of Medicine
Atlanta, GA United States
  Connect »

Steven Papish

Summit Medical Group
Florham Park, NJ United States
  Connect »

Ritesh Parajuli

University of California Irvine - Newport
Orange, CA United States
  Connect »

Kathy Albain

Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood, IL United States
  Connect »

Michelina Cairo

Texas Oncology - Houston Memorial City
Houston, TX United States
  Connect »

Timothy Pluard

Saint Luke's Cancer Institute LLC
Kansas City, MO United States
  Connect »

Joyce O'Shaughnessy

Texas Oncology - Baylor Sammons Cancer Center
Dallas, TX United States
  Connect »

Linda Vahdat

The Whittingham Cancer Center / Norwalk Hospital
Norwalk, CT United States
  Connect »

Hyo Heather Han

H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL United States
  Connect »

Eleni Andreopoulou

Weill Cornell Medical College
New York, NY United States
  Connect »

Patrick Dillon

University of Virginia
Charlottesville, VA United States
  Connect »

Erica Stringer-Reasor

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.